PMID- 26488896
OWN - NLM
STAT- MEDLINE
DCOM- 20160513
LR  - 20220321
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 138
IP  - 6
DP  - 2016 Mar 15
TI  - Proton pump inhibitors and risk of periampullary cancers--A nested case-control 
      study.
PG  - 1401-9
LID - 10.1002/ijc.29896 [doi]
AB  - Considerable attention has been focused on long-term use of proton pump inhibitor 
      (PPI) medications in relation to increased risk of cancer via stimulation of 
      DNA-damaged cells. The aim of this study is to examine the dose-dependent effect 
      of PPI on periampullary cancers in a national population-based cohort. A nested 
      case-control analysis was constructed based on Taiwan's National Health Insurance 
      Research Database and the Taiwan Cancer Registry between the years 2000 and 2010. 
      Cases involving patients diagnosed with periampullary cancers were selected and 
      controls were matched to cases according to age, sex and observational period. A 
      "PPI user" was defined as any patient receiving more than 28 cumulative defined 
      daily doses as measured by prescription drug claims. Conditional logistic 
      regression analysis was conducted to calculate odds ratios (ORs) and 95% 
      confidence intervals (CIs) according to the level of PPI exposure. A total of 
      7,681 cases and 76,762 matched controls were included with a mean follow-up 
      period of 6.6 years (SD: 2.0). The odds of PPI exposure in patients with 
      periampullary cancers were higher than that of control patients with an adjusted 
      OR of 1.35 (95% CIs: 1.16-1.57). Our results also showed that PPI exposure was 
      slightly linked to periampullary cancers in dose-dependent manner. A similar 
      association was observed in patients who solely took PPI but no eradication 
      therapy for Helicobacter pylori infection. Long-term PPI use was associated with 
      an increased risk of periampullary cancers in the current population-based study. 
      Physicians must weigh potential risks of long-term maintenance against 
      therapeutic benefit.
CI  - (c) 2015 The Authors International Journal of Cancer published by John Wiley & Sons 
      Ltd on behalf of UICC.
FAU - Chien, Li-Nien
AU  - Chien LN
AD  - School of Health Care Administration, College of Management, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Huang, Yan-Jiun
AU  - Huang YJ
AD  - Department of General Surgery, Taipei Medical University Hospital, Taipei, 
      Taiwan.
AD  - Ph.D. Program for Translational Medicine, Taipei Medical University & Academia 
      Sinica, Taipei, Taiwan.
FAU - Shao, Yu-Hsuan Joni
AU  - Shao YH
AD  - Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, 
      Taiwan.
FAU - Chang, Chen-Jung
AU  - Chang CJ
AD  - Department of Gastroenterology, Taipei Medical University Hospital, Taipei, 
      Taiwan.
FAU - Chuang, Ming-Tsang
AU  - Chuang MT
AD  - School of Public Health, College of Public Health and Nutrition, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Chiou, Hung-Yi
AU  - Chiou HY
AD  - School of Public Health, College of Public Health and Nutrition, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Yen, Yun
AU  - Yen Y
AD  - Graduate Institute of Cancer Biology and Drug Discovery, College of Medical 
      Science and Technology, Taipei Medical University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151120
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adenocarcinoma/*epidemiology/*etiology
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Comorbidity
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Neoplasms/*epidemiology/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Population Surveillance
MH  - Proton Pump Inhibitors/administration & dosage/*adverse effects
MH  - Registries
MH  - Risk
MH  - Taiwan/epidemiology
PMC - PMC4738410
OTO - NOTNLM
OT  - H. pylori eradication therapy
OT  - nested case-control study
OT  - periampullary cancers
OT  - proton pump inhibitors
EDAT- 2015/10/22 06:00
MHDA- 2016/05/14 06:00
PMCR- 2016/02/03
CRDT- 2015/10/22 06:00
PHST- 2015/07/21 00:00 [received]
PHST- 2015/10/06 00:00 [accepted]
PHST- 2015/10/22 06:00 [entrez]
PHST- 2015/10/22 06:00 [pubmed]
PHST- 2016/05/14 06:00 [medline]
PHST- 2016/02/03 00:00 [pmc-release]
AID - IJC29896 [pii]
AID - 10.1002/ijc.29896 [doi]
PST - ppublish
SO  - Int J Cancer. 2016 Mar 15;138(6):1401-9. doi: 10.1002/ijc.29896. Epub 2015 Nov 
      20.